NOTCH1 and acute lymphoblastic leukemia: Bortezomib, a proteasome inhibitor that exerted its antileukemic action partially through Notch1 downregulation, had additive action in combination with cytarabine in several cell models of T-ALL, but as in cases of other non-specific Notch inhibitors, an additional anti-viability advantage could be attributed to the modulation of other molecular pathways [382].